Form 4 for PFE Pfizer
Accepted 2022-02-25 00:00:00 ET · period of report 2022-02-23 · accession 0001225208-22-003472 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-02-25 | 2022-02-23 | PFE | SUSMAN SALLY | EVP | F - Tax | $49.81 | -57.2K | 109.3K | -34% | -$2.85M |
| D | 2022-02-25 | 2022-02-23 | PFE | SUSMAN SALLY | EVP | M - OptEx | $27.34 | +76.9K | 166.5K | +86% | +$2.10M |
| D | 2022-02-25 | 2022-02-23 | PFE | SUSMAN SALLY | EVP | M - OptEx | $0.00 | -76.9K | 0 | -100% | $0 |
| DM | 2022-02-25 | 2022-02-24 | PFE | SUSMAN SALLY | EVP | A - Grant | $0.00 | +75.5K | 40.2K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-23 | F | D | 19,110 | $46.87 | 147,360 | D | — | — | (F2) The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. |
| 2 | Common | Common Stock | 2022-02-23 | F | D | 38,060 | $51.28 | 109,300 | D | — | — | (F3) The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). (F4) Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. |
| 3 | Common | Common Stock | 2022-02-23 | M | A | 76,895 | $27.34 | 166,470 | D | — | — | (F1) The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). |
| 4 | Derivative | Stock Appreciation Rights | 2022-02-23 | M | D | 76,895 | $0.00 | 0 | D | $27.34 · 2022-02-23 to 2022-02-23 | 76,895 Common Stock | |
| 5 | Derivative | Stock Appreciation Rights | 2022-02-24 | A | A | 35,313 | $0.00 | 35,313 | D | $45.96 · 2029-02-24 to 2029-02-24 | 35,313 Common Stock | (F6) The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. |
| 6 | Derivative | Stock Appreciation Rights | 2022-02-24 | A | A | 40,151 | $0.00 | 40,151 | D | $45.96 · 2027-02-24 to 2027-02-24 | 40,151 Common Stock | (F5) The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. |